Announcement on Obtaining Drug Registration Certificate by Subsidiary
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Obtaining Drug Registration Certificate by Subsidiary
Filed with SSE · · 2 pages · Chinese
Release
Hubei Jumpcan Pharmaceutical Co., Ltd on 6ix
Earlier from Hubei Jumpcan Pharmaceutical
- Announcement on the Release of Pledge for Shares Held by the Controlling Shareholder
- Indicative Announcement on Convening the 1st Extraordinary General Meeting in 2025
- Indicative Announcement on the Use of Self-exercise for the 1st Exercise Period of Stock Options of Initial Grant under the 2022 Restricted Stock and Stock Option Incentive Plan
- Announcement on Progress in Wholly-Owned Subsidiary’s Utilization of Idle Raised Capital for Cash Management, Redemption at Maturity, and Continued Cash Management
- Announcement on Resolutions of the 16th Meeting of the 10th Board of Directors
Later from Hubei Jumpcan Pharmaceutical
- Announcement on Resignation of Non-independent Director and Election of Employee Representative Director
- Announcement on Convening the 2025 Semi-annual Performance Briefing
- Announcement on Lifting Trading Restrictions and Listing of the 1st Trade Restriction Release Period of Initially Granted Restricted Stock under the 2022 Restricted Stock and Stock Option Incentive Plan
- Announcement on Implementation of Independent Exercise in the 1st Exercise Period of Initially Granted Stock Options in 2022 Restricted Stock and Stock Option Incentive Plan
- Report for Q3 2025
Follow Hubei Jumpcan Pharmaceutical into a list and get an email when it puts out news.
Follow Hubei Jumpcan Pharmaceutical